QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:EXAS

Exact Sciences (EXAS) Stock Forecast, Price & News

$81.58
+0.44 (+0.54%)
(As of 05/31/2023 ET)
Compare
Today's Range
$79.69
$81.66
50-Day Range
$62.68
$83.61
52-Week Range
$29.27
$85.82
Volume
1.69 million shs
Average Volume
2.24 million shs
Market Capitalization
$14.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.13

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
3.0% Downside
$79.13 Price Target
Short Interest
Healthy
5.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
1.10mentions of Exact Sciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.32 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.16) to ($1.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

379th out of 1,006 stocks

Medical Laboratories Industry

11th out of 24 stocks


EXAS stock logo

About Exact Sciences (NASDAQ:EXAS) Stock

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

MarketBeat Week in Review – 5/15 - 5/19 (EXAS)
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Exact Sciences (NASDAQ: EXAS)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Stifel Nicolaus Keeps Their Buy Rating on Exact Sciences (EXAS)
Check Out What Whales Are Doing With EXAS
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $100.00
Why Exact Sciences Stock Roared Higher This Week
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $90.00
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $99.00
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings
5/09/2023
Today
5/31/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,400
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$79.13
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
-2.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-623,510,000.00
Pretax Margin
-23.73%

Debt

Sales & Book Value

Annual Sales
$2.08 billion
Book Value
$16.94 per share

Miscellaneous

Free Float
178,129,000
Market Cap
$14.64 billion
Optionable
Optionable
Beta
1.41

Social Links


Key Executives

  • Kevin T. ConroyKevin T. Conroy
    Chairman, President & Chief Executive Officer
  • Jeffrey Thomas ElliottJeffrey Thomas Elliott
    Executive VP, Chief Operating & Financial Officer
  • Sandra Statz
    Senior VP-Clinical & Regulatory Affairs
  • Paul J. Limburg
    Co-Chief Medical Officer & Screening
  • Frederick Baehner
    Co-Chief Medical Officer & Precision Oncology













EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2023?

13 Wall Street analysts have issued 12-month price targets for Exact Sciences' stock. Their EXAS share price forecasts range from $60.00 to $100.00. On average, they anticipate the company's stock price to reach $79.13 in the next twelve months. This suggests that the stock has a possible downside of 2.5%.
View analysts price targets for EXAS
or view top-rated stocks among Wall Street analysts.

How have EXAS shares performed in 2023?

Exact Sciences' stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 63.9% and is now trading at $81.13.
View the best growth stocks for 2023 here
.

Are investors shorting Exact Sciences?

Exact Sciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 9,810,000 shares, a decrease of 11.7% from the April 30th total of 11,110,000 shares. Based on an average daily trading volume, of 2,070,000 shares, the days-to-cover ratio is currently 4.7 days.
View Exact Sciences' Short Interest
.

When is Exact Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our EXAS earnings forecast
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.37. The medical research company had revenue of $602 million for the quarter, compared to the consensus estimate of $543.18 million. Exact Sciences had a negative trailing twelve-month return on equity of 16.64% and a negative net margin of 23.49%. Exact Sciences's quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.04) earnings per share.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.38 billion-$2.42 billion, compared to the consensus revenue estimate of $2.30 billion.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.38%), Baillie Gifford & Co. (2.66%), Sumitomo Mitsui Trust Holdings Inc. (2.12%), Nikko Asset Management Americas Inc. (1.83%), Ensign Peak Advisors Inc (1.58%) and Artisan Partners Limited Partnership (1.51%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Sarah Condella and Torsten Hoof.
View institutional ownership trends
.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $81.13.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $14.64 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Exact Sciences have?

The company employs 6,400 workers across the globe.

Does Exact Sciences have any subsidiaries?
The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -